Blog Posts
-
July 20, 2017A busy news week focuses on drug access and costsPatent extensions upheld and revealed
On Monday, July 17th, a US appeals court ruled that a patent on Takeda Pharmaceutical’s drug Velcade® (bortezomib) was extended to 2022. Generic drug...
-
July 13, 2017CAR T-cell therapy wins expert panel approval for leukemia treatment: What does...On Wednesday, an advisory panel convened by the US Food and Drug Administration (FDA) voted 10 to 0 to recommend the approval of CAR T-cell therapy for treatment of children and young adults with...
-
July 06, 2017In the News: The Search to Achieve a Cure Is Never EasyYesterday the FDA halted a third Merck myeloma trial involving the checkpoint inhibitor pembrolizumab (Keytruda®). In all three trials, Keynote 183, 185, and 023, there have been more deaths among...
-
June 29, 2017Global Myeloma Voices Come Together to Drive Research and Improve Lives of...This past week was very busy and important for the global myeloma community, which is increasingly coming together with a single voice for myeloma research and patient care. In Madrid, Spain, on...
-
June 08, 2017Are Cure Claims for CAR T-Cell Therapy Premature?The top news to come out of the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), which concluded on Tuesday, focused on claims that immune cellular therapy with CAR T-cells...
- 1 of 11
- next page
